ABSTRACTS (e-)POSTER PRESENTATIONS
P3.05 Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation
A. Jaspers, F. Baron, J. Maertens, B. De Prijck, R. Schots, C. Bonnet, K. Hafraoui, E. Willems, S. Servais, G. Fillet, Y. Beguin
P3.13 Plerixafor in autologous haematopoietic stem cell mobilization in Belgium
D. Selleslag, C. Lambert, P. Zachée, D. Dierickx
P3.12 Devised performance as a tool for public engagement in acute haematological cancers
A. Mermikides, M. Mermikides, A. Tanczos, R. Seymour, A. Kirkham, C. Lofthouse, A. Nasrat, E. Weitkamp, A. Van de Velde
P3.11 Remitting seronegative symmetrical synovitis with pitting edema after allogeneic stem cell transplantation
A. Devresse, S. Daens, R. Lhommel, L. Knoops, D. Bauwens, E. Van den Neste, X. Poiré
P3.10 Kaposi’s Sarcoma: a rare complication reflecting immune suppression after autologous stem cell transplantation
B. Heyrman, A. De Becker, K. Fostier, F. Trullemans, R. Schots
P3.09 Occurrence of mild spontaneous graft-versus-host-disease after autologous stem cell transplantation for multiple myeloma
I. Moors
P3.08 Multifocal periostitis as a long-term complication of voriconazole use in an allogeneic stem cell transplant recipient
P. Vlummens, P. Gykiere, B. Lambert, E. Steel, T. Kerre
P3.07 Primary intestinal aspergillosis resulting in acute intestinal volvulus after autologous stem cell transplantation in a patient with relapsed non-Hodgkin lymphoma: a rare infectious complication
P. Vlummens, D. van de Putte, L. Libbrecht, L. Noens, V. Van Hende, T. Kerre
P3.06 Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation following Flu-TBI versus TLI-ATG Conditioning
M. Hannon, Y. Beguin, G. Ehx, S. Servais, L. Seidel, C. Graux, J. Maertens, T. Kerre, C. Daulne, M. De Bock, M. Fillet, A. Ory, E. Willems, A. Gothot, S. Humblet-Baron, F. Baron
P3.14 Effects of the immunomodulating peptide thymosin alpha 1 in multiple myeloma and immune reconstitution after hematopoietic stem cell transplantation in murine models
M. Binsfeld, M. Hannon, S. Humblet-Baron, Y. Beguin, F. Baron, J. Caers
P3.04 Effects of tocilizumab® on Th17 cells differentiation in a humanized mouse model of xenogenic graft-versus-host disease
L. Delens, S. Servais, M. Hannon, G. Ehx, G. Fransolet, S. Dubois, Y. Beguin
P3.03 Study of immune recovery in a randomized phase II trial of sequential double autologous transplantation with unmanipulated or AC133+ PBSC in patients with multiple myeloma
M. Hannon, S. Servais, R. Schots, E. Castermans, L. Seidel, A. Gothot, E. Baudoux, O. Giet, N. Wanten, E. Willems, C. Daulne, I. Van Riet, Y. Beguin, F. Baron
P3.02 Autologous Hematopoietic Stem Cell Transplantation in Crohn’s Disease: Results from our first 14 patients
D. Dierickx, A. Van Besien, S. Vermeire, G. Verhoef, M. Delforge, T. Devos, A. Janssens, J. Maertens, H. Schoemans
P3.01 Hematopoietic progenitor cell count in mobilized peripheral blood by Sysmex XE-2100: added value in clinical practice?
S. Desmet, T. Maenhout, E. Moreau, I. Van Haute, D. Deeren
P2.10 Acquired von Willebrand disease in CML : a case report
C. Amicone, L. Plawny
P2.09 Refractory anemia with ringed sideroblasts upon linezolid treatment
K. Vanhouteghem, B. Cauwelier, P. Costers, D. Selleslag, J. Emmerechts
P2.08 Short delay of occurrence of myelodysplasia after Peptide Receptor Radionuclide Therapy (PRRT) in neuroendocrine tumors (NETs)
G. Claes, J. Nguyen, N. Charette, G. Machiels, M. Vercruyssen, S. Wittnebel, N. Meuleman, D. Bron
P2.07 MPN with JAK2 V617F mutation and identical del20q11.2 in three first-degree relatives without identified germline defect
J. Dauw, E. Boone, N. Cardinaels, E. Moureau, A. Nijs, F. Nollet, V. Van Hende, N. Van Roy, K. Van Eygen
P3.15 Clofarabine as salvage therapy and bridge to transplantation in acute leukemia. A single center experience
G. Di Prinzio, C. Cornil, E. Collinge, A. Devresse, P.D.M. Katoto, V. Havelange, E. Van den Neste, X. Poiré, M-C. Vekemans
P3.17 Azacytidine prevents experimental sclerodermic chronic graft-versus-host disease
G. Fransolet, G. Ehx, J. Somja, L. Belle, P-V. Drion, S. Humblet-Baron, Y. Beguin, B. Baron
P3.19 Spurious Decrease In The Wbc Count Measured By The Wnr Channel Of Xn Haematology Analyzer (Sysmex) Could Be Associated With Metastatic Adenocarcinoma
V.T.P. Nguyen, D. Gobin, R. Li, B. Cantinieaux
P4.01 Retrospective study of the significance of positive DAT
H. Claerhout, K. Ver Elst, S. Weekx, S. Vermeiren
P4.02 Hepcon® HMS and Hemochron® allow for similar anticoagulation management during cardiopulmonary bypass in low-risk patients undergoing cardiac surgery
C. Lecut, C. Clotuche, M.G. Lagny, P. Péters, J.O. Defraigne, A. Gothof, R. Larbuisson
P4.03 Introduction of Type and Screen testing in patients from the hematology and oncology department: comparison with blood cross-matching
M. Hofmans, P. Meeus, E. Bailleul
P4.04 Point-of-care devices assessing platelet function and clotting in sepsis: effect of thrombocytopenia and analytical variables
A. Gothot, C. Gosset, C. Lecut, P. Péters, P. Massion
P4.05 Anemia in a geriatric hospitalized population: an old disorder
L. Sattar, P. Hermans, T. Pepersack
P4.06 A pernicious anemia hiding under the guise of a normocytic anemia
A. Dermine, J. Dewulf, J-P. Defour, M-C. Vekemans
P4.07 Diagnosis of congenital von Willebrand disease during a pre-operative screening in a multiple myeloma patient
M. EI Ouaaliti, L Rong, P. Nguyen, D. Gobin, D. Bron, B. Cantinieaux
P4.08 Two cases of immune-mediated early-onset neonatal thrombocytopenia: a case presentation
K. Vanhouteghem, H. Vanhouteghem, K. De Schynkel, K. Van Haver, A. Luyckx
P4.09 Evaluation of Schistocyte Analysis by a Novel Automated Digital Cell Morphology Application
AS. Hervent, M. Godefroid, B. Cauwellier, J. Billiet, J. Emmerechts
P4.10 De novo thrombotic microangiopathy after non-renal solid organ transplantation
D. Dierickx, A. Verbiest, J. Pirenne, G. Verhoef, M. Delforge, T. Devos, A. Janssens, J. Maertens, H. Schoemans
P4.11 Influence of platelet clumps on platelet function analyzer (PFA)-200® testing
S. Mulliez, G. Hallaert, D. van Roost, A. Vantilborgh, K. Devreese
P4.12 Comparison Between Polyspecific Reagent And Anti-Igg For The Detection Of Irregular Antibodies By Indirect Antiglobulin Test With Biovue-Ortho®
N. Tasiaux, J. Honoré, A. Dascotte, C. Potvliege
P1.11 Primary Cutaneous T-cell Lymphoproliferative Disorders Expressing a CD8 and CD30-Positive Phenotype
M. Shwe, L. Marot, L. Sacre, A. Camboni, S. Olivier
P1.01 Myeloid Derived Suppressor Cells induce Multiple Myeloma cell survival through AMPK activation
K. De Veirman, J. van Ginderachter, N. De Beule, S. Lub, A. Maes, E. De Bruyne, E. Menu, I. Van Riet, K. Vanderkerken, E. Van Valckenborgh
P1.02 In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma
K. Maes, E. De Smedt, A. Kassambara, D. Hose, A. Seckinger, E. Van Valckenborgh, E. Menu, B. Klein, K. Vanderkerken, J. Moreaux, E. De Bruyne
P1.03 Thymoquinone induces DNA damage, apoptosis and inhibits proliferation in germinal center subtype of diffuse large B-cell lymphoma
M. Berehab, R. Rouas, D. Douaa, D. Bron, P. Lewalle, P. Martiat, M. Merimi
P1.06 Bilateral Bell’s palsy leading to the diagnosis of chronic lymphocytic leukemia
C. Cornil, E. Collinge, G. Di Prinzio, A. Devresse, J-P. Defour, P. Saussoy, L. Michaux, L. Knoops, M-C. Vekemans, A. Ferrant
P1.07 Unusual progression of a B-cell non-Hodgkin’s lymphoma
E. Collinge, A. vanden Daelen, L. Marot, A. Camboni, J-P. Defour, P. Saussoy, L. Michaux, M-C. Vekemans, L. Knoops
P1.08 Multiparameter flow cytometric analysis of composite lymphoma: case report of a mantle cell lymphoma associated with a B-cell chronic lymphocytic leukemia and an aberrant T cell subset
J. Foguenne, M. Simul, R. Keutgens, F. Tassin, C. Bonnet, Y. Beguin, M. Jamar, F. Lambert, A. Gothot
P1.09 Follicular dendritic cell sarcoma in the retropharyngeal region: diagnostic and therapeutic challenges
H.R. Kourie, J. Nguyen, X. Wang, T. Gil, R. Dewind, P. Lewalle, N. Meuleman, D. Bron
P1.10 Lactic acidosis as an atypical presentation of a diffuse large B-cell lymphoma
V. Galle, C. De Vriendt, P. Vlummens, A. Vantilborgh, D. Benoit, E. De Coster
P1.12 Tumor lysis syndrome: monocentric evaluation of a predictive tool
D. Dierickx, K. Saevels, G. Verhoef, M. Delforge, T. Devos, A. Janssens, J. Maertens, H. Schoemans
P1.13 Temsirolimus in daily clinical practice: results from the Belgian mantle cell lymphoma registry
A. Janssens, V. Vergote, A. Van Hoof, All Other Members of The BHS
P1.14 Monoclonal B-cell lymphocytosis (MBL): results of a routine screening in a general hospital
G. Claes, D. Bron, M. Maerevoet, S. Benghiat, V. De Wilde, B. Bailly, N. Istaces, J. Brauner, O. Pradier, N. Meuleman
P1.15 Outcome after salvage chemotherapy with DHAP/ICE-type regimens and attempt to transplant in patients with aggressive lymphoma: experience of a single centre
P.D.M. Katoto, N. Vanlangendonck, V. Havelange, X. Poiré, C. Lambert, M-C. Vekemans, A. Ferrant, V. Lannoy, E. Van den Neste
P1.16 Monoclonal B-cell lymphocytosis (MBL): results olmpact of extracellular vesicles from mesenchymal stromal cells-based microenvironment on Chronic Lymphocytic Leukemia B-cells
E. Crompot, M. Van Damme, H. Duvillier, K. Pieters, P. Mineur, N. Meuleman, D. Bron, L.L. Lagneaux, B. Stamatopoulous
P1.17 DNA hydroxymethylation in chronic lymphocytic leukemia: TET and IDH mRNA expression, prognostic significance and influence of microenvironment
M. Van Damme, E. Crompot, N. Meuleman, P. Mineur, D. Bron, L. Lagneaux, B. Stamatopoulos
P1.18 Monoclonal B-cell lymphocytosis with a lymphoma phenotype: characterization and prognosis of a patient cohort
S. Vander Meeren, B. Heyrman, W. Renmans, K. Jochmans, M. Bakkus, H. De Raeve, R. Schots, M. De Waele
P1.19 The role of the Anaphase Promoting Complex/ Cyclosome in multiple myeloma cell growth
S. Lub
P1.20 Intravascular lymphoma: A retrospective monocentric observational analysis and review of literature
D. Dierickx, D. Gullentops, G. Verhoef, S. Vanderschueren, T. Tousseyn, O. Gheyssens, M. Delforge, T. Devos, A. Janssens, J. Maertens, H. Schoemans
P1.22 Characteristics, treatment and prognosis of primary central nervous system lymphoma: a single center retrospective study
D. Dierickx, A. van Mellaert, L. Smets, G. Verhoef, P. Clement, P. Demaerel, T. Tousseyn, M. Delforge, T. Devos, A. Janssens, J. Maertens, H. Schoemans
P2.01 Functional evaluation of T cells generated from WT1-TCR transduced human hematopoietic stem cells using the OP9-DL1 coculture system
S. Bonte, S. Snauwaert, G. Goetgeluk, M.H.M. Heemskerk, H. Stauss, R. Stripecke, B. Vandekerckhove, T. Kerre
P2.03 Belgian Stop IMatinib trial
P. Mineur, C. Doyen, N. Straetmans, K. Van Eygen, D. Pranger, A. Bosly, M. André, T. Devos, L. Knoops
P2.04 Role of microvesicles derived from leukemic blast in DIC and thrombosis.
D. Gheldof, J-M. Dogné, C. Graux, G. Fabienne, A. Sonet, B. Chatelain, F. Mullier, C. Chatelain
P2.05 Role of extracellular vesicles on multidrug resistance transfer between leukemia cells
C. Bouvy, D. Gheldof, C. Chatelain, F. Mullier, J-M. Dogné
P2.06 Cost Analysis of Immunotherapy Using Dendritic Cells for Acute Myeloid Leukemia Patients
A. Van de Velde, S. Anguille, P. Beutels, S. Dom, I. Cornille, G. Nijs, F. van Tendeloo, E.L. Smits, A. Verlinden, A.P. Gadisseur, W.A. Schroyens, Z.N. Berneman
Top
